Angiogenesis and reproduction

British Journal of Obstetrics and Gynaecology

Volumn 108, Issue 8, 2001, Pages 777-783

  Smith, S K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CONTRACEPTIVE AGENT; EPHRIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTEGRIN; NEUROPILIN; PEPTIDE; POSTCOITUS CONTRACEPTIVE AGENT; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; SEMAPHORIN 3A; SEMAPHORIN IV; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BLOOD VESSEL; CONTRACEPTION; ENDOMETRIOSIS; ENDOMETRIUM; GYNECOLOGIC CANCER; HUMAN; INTRAUTERINE GROWTH RETARDATION; MENORRHAGIA; MENSTRUAL CYCLE; OVARY; OVARY CYCLE; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; REPRODUCTION; REVIEW; UTERUS BLEEDING;

ANGIOGENESIS INHIBITORS; CONTRACEPTION; ENDOMETRIUM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OVARY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; REPRODUCTION;

EID: 0034928778     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-5456(00)00211-4     Document Type: Review

References (88)

1. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system
2. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
3. Vasculogenesis
4. Angiogenesis in cancer, vascular, rheumatoid and other disease
5. Mechanism of blood vessel formation
6. Vascular development: Cellular and molecular regulation
7. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix
8. Angiogenesis in embryos and ischemic diseases
9. The biology of vascular endothelial growth factor
10. Biphasic effect of transforming growth factor-beta1 on in vitro angiogenesis
11. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
12. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
13. Angiostatin induces and sustains dormancy of human primary tumours in mice
14. Mechanisms of angiogenesis
15. Requirement of vascular integrin alpha(v)beta3 for angiogenesis
16. VEGF deprivation-induced apoptosis is a component of programmed capillary regression
17. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
18. Signalling vascular morphogenesis and maintenance
19. Pericytes in the microvasculature
20. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
21. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
22. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
23. Matrix metalloproteinases and endometrial remodelling
24. Collagenase and related matrix metalloproteinases: A prominent role in the initiation of menstruation?
25. Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells
26. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle
27. A biological model for the regulation of peri-implantation hemostasis and menstruation
28. Focal cellular origin and regulation of interstitial collagenase (matrix metalloproteinase-1) are related to menstrual breakdown in the human endometrium
29. Endometrium: Tissue remodelling and regeneration
30. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel
31. Endometrial endothelial cell proliferation during the menstrual cycle
32. Endothelial cell migratory signal produced by human endometrium during the menstrual cycle
33. Endometrial microvascular growth in normal and dysfunctional states
34. Endometrial vascular smooth muscle oestrogen and progesterone receptor distribution in women with and without menorrhagia
35. Angiogenesis, vascular endothelial growth factor and the endometrium
36. Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation
37. Vascular smooth muscle alpha-actin distribution around endometrial arterioles during the menstrual cycle: Increased expression during the perimenopause and lack of correlation with menorrhagia
38. Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium
39. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding
40. Angiogenic activity of peritoneal fluid from women with endometriosis
41. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis
42. Cell proliferation is increased in the endometrium of women with endometriosis
43. Angiogenesis in endometriosis
44. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids
45. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
46. Vascular endothelial growth factor and corpus luteum angiogenesis
47. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
48. Vasculogenesis in early human placental villi: An ultrastructural study
49. Functions of the VEGF receptor-1 (FLT-1) in the vasculature
50. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
51. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: A strategy for successful endovascular invasion?
52. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
53. Alternative splicing of vascular endothelial growth factor (VEGF)-R1(FLT-1) pre-mRNA is important for the regulation of VEGF activity
54. Endothelial dysfunction in preeclampsia
55. Toxaemias of pregnancy
56. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
57. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies-complicated by pre-eclampsia
58. VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: Implications in the pathogenesis of preeclampsia
59. Preeclampsia is associated with reduced serum levels of placenta growth factor
60. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma
61. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
62. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
63. Changes in tumorigenesis- and angiogenesis-related gene expression in ovarian cancer detected by tailored high density cDNA arrays
64. Administration of gonadotrophins stimulates proliferation of normal mouse ovarian surface epithelium
65. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma
66. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia
67. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer
68. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
69. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
70. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo
71. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas
72. Changes in insulin-like growth factor-binding protein-3 messenger ribonucleic acid in endothelial cells of the human corpus luteum: A possible role in luteal development and rescue
73. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis
74. Angiogenesis and ovarian cancer
75. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
76. Integrin alpha(v)beta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessel
77. Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470)
78. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endotyhelial growth factor
79. Neuropilin-1 is a placenta growth factor-2 receptor
80. Neuropilin-2 is a receptor for semaphorin IV: Insight into the structural basis of receptor function and specificity
81. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border
82. Manipulating angiogenesis: From basic science to the bedside
83. Growth factor antagonists for the treatment of diabetic vascular complications
84. Endothelial dysfunction and pathogenesis of diabetic angiopathy
85. Angiogenesis: Implications for rheumatoid arthritis
86. Tumor development under angiogenic signalling: A dynamic theory of tumor